The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including depression. The agency announced the move Friday, several days after President Donald Trump signed an executive order calling to speed up access to the mind-altering drugs. The move reflects growing popular support for the mind-altering substances among Trump’s supporters, including combat veterans and followers of the Make America Healthy Again movement. The FDA also greenlighted initial testing of a drug related to ibogaine, a potent psychedelic known to cause dangerous heart rhythms.